Arvee Laboratories (India) Ltd. (IN:ARVEE)
:ARVEE
ARVEE Stock Chart & Stats
₹242.32
-₹0.03(-0.02%)
At close: 4:00 PM EST
₹242.32
-₹0.03(-0.02%)
Day’s Range― - ―
52-Week Range₹129.11 - ₹290.78
Previous CloseN/A
Volume716.00
Average Volume (3M)1.40K
Market Cap
₹1.70B
Enterprise Value₹1.87B
Total Cash (Recent Filing)₹59.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)32.2
Beta0.91
Next Earnings
May 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.66
Shares Outstanding11,020,000
10 Day Avg. Volume2,098
30 Day Avg. Volume1,398
Financial Highlights & Ratios
PEG Ratio0.72
Price to Book (P/B)5.18
Price to Sales (P/S)4.20
P/FCF Ratio-93.28
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Capital StructureLow leverage and a strong equity ratio provide durable financial flexibility. This reduces bankruptcy risk, supports investment in product development or capacity during downturns, and preserves the ability to access credit for strategic needs over the next 2–6 months.
Stable Profit MarginsConsistently stable gross and net margins, with recent EBIT/EBITDA improvement, imply operational resilience and cost discipline. Sustained margins allow the firm to absorb revenue shocks and maintain profitability, supporting reinvestment and shareholder returns over time.
Pharma / Specialty Chemicals PositioningOperating in pharmaceuticals and specialty chemicals gives structural demand and higher barriers to entry than commodity chemicals. Niche product focus and regulatory moats can support enduring customer relationships and pricing power across cycles.
Bears Say
Revenue DeclineA material recent revenue drop and inconsistent top-line growth reduce scale economies and pressure fixed-cost leverage. Persistent revenue volatility undermines planning, weakens negotiating leverage with suppliers/customers, and constrains organic investment capacity.
Weak Cash ConversionNegative free cash flow and poor cash conversion signal earnings quality issues and limited internal funding. Over time this forces reliance on external financing for capex or working capital, increasing execution risk and restricting the firm's ability to pursue growth initiatives.
Small Scale / Limited Operating BaseA small workforce implies limited scale, narrower product breadth and potentially concentrated customer exposure. This can magnify operational disruptions, limit R&D and commercial reach, and make it harder to absorb regulatory or competitive shocks over the medium term.
Arvee Laboratories (India) Ltd. News
ARVEE FAQ
What was Arvee Laboratories (India) Ltd.’s price range in the past 12 months?
Arvee Laboratories (India) Ltd. lowest stock price was ₹129.11 and its highest was ₹290.78 in the past 12 months.
What is Arvee Laboratories (India) Ltd.’s market cap?
Arvee Laboratories (India) Ltd.’s market cap is ₹1.70B.
When is Arvee Laboratories (India) Ltd.’s upcoming earnings report date?
Arvee Laboratories (India) Ltd.’s upcoming earnings report date is May 22, 2026 which is in 42 days.
How were Arvee Laboratories (India) Ltd.’s earnings last quarter?
Arvee Laboratories (India) Ltd. released its earnings results on Feb 13, 2026. The company reported ₹1.658 earnings per share for the quarter, beating the consensus estimate of N/A by ₹1.658.
Is Arvee Laboratories (India) Ltd. overvalued?
According to Wall Street analysts Arvee Laboratories (India) Ltd.’s price is currently Overvalued.
Does Arvee Laboratories (India) Ltd. pay dividends?
Arvee Laboratories (India) Ltd. does not currently pay dividends.
What is Arvee Laboratories (India) Ltd.’s EPS estimate?
Arvee Laboratories (India) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arvee Laboratories (India) Ltd. have?
Arvee Laboratories (India) Ltd. has 11,020,000 shares outstanding.
What happened to Arvee Laboratories (India) Ltd.’s price movement after its last earnings report?
Arvee Laboratories (India) Ltd. reported an EPS of ₹1.658 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.977%.
Which hedge fund is a major shareholder of Arvee Laboratories (India) Ltd.?
Currently, no hedge funds are holding shares in IN:ARVEE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arvee Laboratories (India) Ltd.
Arvee Laboratories (India) Ltd. manufactures and sells various specialized chemicals in India. The company provides polymer modifiers, including dimethyl 5-sodiosulfoisophthalate, 5-sulfoisophthalic acid mono sodium salt, 5-sulfoisophthalic acid mono lithium salt, and 5-sodiosulfo-bis-(ß-hydroxyethyl)-isophthalate; and contrast media intermediates, such as 5-nitroisophthalic acid, dimethyl 5-nitroisophthalate, monomethyl 5-nitroisophthalate, 5-hydroxyisophthalic acid, 5-aminoisophthalic acid, and dimethyl 5-aminoisophthalate, as well as 3,5-dinitrobenzoic acid and 3,5-diamino benzoic acid. It also offers drug intermediates comprising 2-acetyl thiophene, thiophene-2-carboxaldehyde, 4amino pyridine, and 2chloro5nitrobenzoic acid. In addition, the company exports its products. Arvee Laboratories (India) Ltd. was incorporated in 2012 and is based in Ahmedabad, India.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Lasa Supergenerics Ltd.
―
Vivimed Labs Limited
―